The impact of blood pressure lowering agents on the risk of worsening frailty among patients with diabetes mellitus: a cohort study.

IF 4.1 Q2 GERIATRICS & GERONTOLOGY

npj aging Pub Date : 2024-10-07 DOI:10.1038/s41514-024-00173-1

Jui Wang, Szu-Ying Lee, Chia-Ter Chao, Jenq-Wen Huang, Kuo-Liong Chien

{"title":"The impact of blood pressure lowering agents on the risk of worsening frailty among patients with diabetes mellitus: a cohort study.","authors":"Jui Wang, Szu-Ying Lee, Chia-Ter Chao, Jenq-Wen Huang, Kuo-Liong Chien","doi":"10.1038/s41514-024-00173-1","DOIUrl":null,"url":null,"abstract":"<p><p>Patients with diabetes mellitus (DM) are at risk of developing frailty, but studies rarely addressed risk factors for frailty worsening. We investigated whether blood pressure (BP)-lowering agents influenced such risk in these patients. Adults with type 2 DM were identified from National Taiwan University Hospital, with the primary outcome, the worsening of frailty by ≧1 score increase of FRAIL scale determined. We used the Cox proportional hazards analysis to derive the risk of worsening frailty associated with BP-lowering agents. Among 41,440 patients with DM, 27.4% developed worsening frailty after 4.09 years of follow-up. Cox regression revealed that diuretics (hazard ratio (HR) 1.12, 95% confidence interval (CI) 1.06-1.18) and α-blocker (HR 1.14, 95% CI 1.06-1.23) users had a significantly higher risk of worsening frailty than non-users, whereas the risk was lower among β-blocker users (HR 0.93, 95% CI 0.88-0.98). It would be therefore prudent to weigh the advantages and disadvantages of using specific BP-lowering agent classes.</p>","PeriodicalId":94160,"journal":{"name":"npj aging","volume":"10 1","pages":"44"},"PeriodicalIF":4.1000,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11458616/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"npj aging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/s41514-024-00173-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Patients with diabetes mellitus (DM) are at risk of developing frailty, but studies rarely addressed risk factors for frailty worsening. We investigated whether blood pressure (BP)-lowering agents influenced such risk in these patients. Adults with type 2 DM were identified from National Taiwan University Hospital, with the primary outcome, the worsening of frailty by ≧1 score increase of FRAIL scale determined. We used the Cox proportional hazards analysis to derive the risk of worsening frailty associated with BP-lowering agents. Among 41,440 patients with DM, 27.4% developed worsening frailty after 4.09 years of follow-up. Cox regression revealed that diuretics (hazard ratio (HR) 1.12, 95% confidence interval (CI) 1.06-1.18) and α-blocker (HR 1.14, 95% CI 1.06-1.23) users had a significantly higher risk of worsening frailty than non-users, whereas the risk was lower among β-blocker users (HR 0.93, 95% CI 0.88-0.98). It would be therefore prudent to weigh the advantages and disadvantages of using specific BP-lowering agent classes.

查看原文本刊更多论文

降压药对糖尿病患者衰弱恶化风险的影响：一项队列研究。

糖尿病（DM）患者有罹患虚弱症的风险，但研究很少涉及虚弱症恶化的风险因素。我们研究了降压药是否会影响这些患者的这种风险。我们从国立台湾大学医院找到了患有 2 型糖尿病的成年人，主要结果是 FRAIL 评分增加≧1 分的虚弱恶化程度。我们使用 Cox 比例危险度分析得出了与降压药相关的虚弱恶化风险。在 41440 名糖尿病患者中，27.4% 的患者在随访 4.09 年后出现虚弱恶化。Cox 回归显示，使用利尿剂（危险比 (HR) 1.12，95% 置信区间 (CI)1.06-1.18）和α-受体阻滞剂（HR 1.14，95% CI 1.06-1.23）的患者发生虚弱恶化的风险明显高于未使用的患者，而使用β-受体阻滞剂的患者发生虚弱恶化的风险较低（HR 0.93，95% CI 0.88-0.98）。因此，权衡使用特定降压药物类别的利弊是明智之举。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

npj aging

CiteScore

8.90

自引率

0.00%

发文量